Holen Sie sich die Stockscreener-App
36.93
1.05%
0.42
Schlusskurs vom Vortag:
$36.51
Offen:
$36.66
24-Stunden-Volumen:
408.56K
Relative Volume:
0.35
Marktkapitalisierung:
$3.87B
Einnahmen:
$7.70M
Nettoeinkommen (Verlust:
$-465.32M
KGV:
-7.4688
EPS:
-4.9446
Netto-Cashflow:
$-383.68M
1W Leistung:
-3.49%
1M Leistung:
-13.59%
6M Leistung:
+8.51%
1J Leistung:
+5.29%
1-Tages-Spanne:
$35.85
$37.37
1-Wochen-Bereich:
$35.43
$39.28
52-Wochen-Spanne:
$24.10
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
36.94 | 3.82B | 7.70M | -465.32M | -383.68M | -4.9446 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.57 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.28 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.71 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.76 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.67 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Hochstufung | Goldman | Neutral → Buy |
| 2025-07-10 | Eingeleitet | Goldman | Neutral |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-11 | Eingeleitet | TD Cowen | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-12-21 | Eingeleitet | Jefferies | Hold |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Eingeleitet | ROTH Capital | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-13 | Eingeleitet | JP Morgan | Neutral |
| 2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
| 2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - simplywall.st
Income Plays: Can Crinetics Pharmaceuticals Inc stock outperform in a bear market2026 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Systematic review on acromegaly therapies receives journal approval, Crinetics Pharmaceuticals announces - Traders Union
(CRNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
WINTON GROUP Ltd Takes Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Levels Update: Is Crinetics Pharmaceuticals Inc a stock for growth or value investorsMarket Activity Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf. - Yahoo Finance
Should value investors consider Crinetics Pharmaceuticals Inc2026 Year in Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Will Crinetics Pharmaceuticals Inc. stock attract more institutional investorsInsider Buying & High Win Rate Trade Alerts - Naître et grandir
Insider Trends: What is the dividend yield of Crinetics Pharmaceuticals IncJuly 2025 Pullbacks & High Conviction Investment Ideas - baoquankhu1.vn
American Century Companies Inc. Has $47.21 Million Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharma CFO Schilke sells $266k in stock By Investing.com - Investing.com Canada
Crinetics Pharma CFO Schilke sells $266k in stock - Investing.com
Insider Sell: Stephanie Okey Sells 3,000 Shares of Crinetics Pha - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Director Stephanie Okey Sells 3,000 Shares - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) CFO Tobin Schilke Sells 6,713 Shares - MarketBeat
CRNX: Strong launch, advancing pipeline, and EU expansion position for major growth in rare endocrine diseases - TradingView
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Crinetics Pharmaceuticals (CRNX) Stock Analysis: Unpacking a 105% Potential Upside for Growth Investors - DirectorsTalk Interviews
Why Crinetics Pharmaceuticals (CRNX) Is Down 7.1% After Deeper 2025 Loss And New US$207 Million Shelf Registration - Sahm
Does Crinetics Pharmaceuticals, Inc. (CRNX) Have Momentum? - AAII.com
CRNX: Analyst Maintains "Market Outperform" but Lowers Price Tar - GuruFocus
Citizens Jmp Cuts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $96.00 - MarketBeat
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
(CRNX) Risk Channels and Responsive Allocation - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen - MarketBeat
Crinetics Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CRNX) 2026-02-27 - Seeking Alpha
Crinetics Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Vanguard Group Inc. Sells 86,003 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Is Palsonfi Launch Momentum And ESOP Shelf Registration Altering The Investment Case For Crinetics (CRNX)? - Yahoo Finance
Crinetics Pharmaceuticals Inc (CRNX) Q4 2025 Earnings Call Highl - GuruFocus
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus
Crinetics Pharmaceuticals (CRNX) Reports Strong Q4 2025 Performa - GuruFocus
Crinetics Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Crinetics Pharmaceuticals Q4 2025 earnings beat forecasts - Investing.com
Crinetics (CRNX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Crinetics Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Crinetics (CRNX) Exceeds Revenue Expectations and Looks to Expan - GuruFocus
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Crinetics Pharmaceuticals Q4 Loss Widens - marketscreener.com
Earnings Flash (CRNX) Crinetics Pharmaceuticals Posts Q4 Loss $1.29, vs. FactSet Est of $1.35 Loss - marketscreener.com
Crinetics Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (CRNX) Crinetics Pharmaceuticals, Inc. Reports Q4 Revenue $6.2M, vs. FactSet Est of $4.5M - marketscreener.com
Crinetics Pharmaceuticals Reports $5.4 Million in Q4 2025 Net Revenue from PALSONIFY™ and Plans for Phase 2/3 Study of Atumelnant in 2026 - Quiver Quantitative
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance
Crinetics earnings on deck: Can drug launch offset mounting losses? - Investing.com Australia
Crinetics earnings on deck: Can drug launch offset mounting losses? By Investing.com - Investing.com South Africa
JPMorgan Chase & Co. Grows Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Crinetics Pharmaceuticals Inc-Aktie (CRNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Okey Stephanie | Director |
Mar 03 '26 |
Sale |
39.67 |
3,000 |
119,010 |
13,300 |
| Schilke Tobin | Chief Financial Officer |
Mar 03 '26 |
Sale |
39.67 |
6,713 |
266,305 |
78,121 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):